Literature DB >> 10584678

Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration.

G Ebersbach1, M Stöck, J Müller, G Wenning, J Wissel, W Poewe.   

Abstract

Nicotine has been reported to have positive effects on motor performance in patients with Parkinson's disease. In this study, motor performance was evaluated in 16 patients with idiopathic Parkinson's disease during a practical off-period using the motor part of the Unified Parkinson's Disease Rating Scale after 12 hours' exposure to a transdermal patch containing 35 mg nicotine or placebo. The study was performed using a double-blind crossover design. In contrast to previous reports, nicotine exposure was followed by a worsening of symptoms compared with placebo. A negative response to subthreshold dopaminergic stimulation, resulting from an inhibitory effect of low striatal dopamine concentrations acting on a subset of dopamine receptors, might possibly account for this finding.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10584678     DOI: 10.1002/1531-8257(199911)14:6<1011::aid-mds1016>3.0.co;2-f

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  30 in total

1.  Effects of nicotine chewing gum on a real-life motor task: a kinematic analysis of handwriting movements in smokers and non-smokers.

Authors:  Oliver Tucha; Klaus W Lange
Journal:  Psychopharmacology (Berl)       Date:  2003-12-11       Impact factor: 4.530

Review 2.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

3.  Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry.

Authors:  Paula L Vieira-Brock; Eleanor I Miller; Shannon M Nielsen; Annette E Fleckenstein; Diana G Wilkins
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-09-18       Impact factor: 3.205

Review 4.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

5.  Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease.

Authors:  Maryka Quik; Archana Mallela; Jason Ly; Danhui Zhang
Journal:  Mov Disord       Date:  2013-07-08       Impact factor: 10.338

Review 6.  Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders.

Authors:  Maryka Quik; James T Boyd; Tanuja Bordia; Xiomara Perez
Journal:  Nicotine Tob Res       Date:  2019-02-18       Impact factor: 4.244

7.  Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.

Authors:  Maryka Quik; Li Chen; Neeraja Parameswaran; Xinmin Xie; J William Langston; Sarah E McCallum
Journal:  J Neurosci       Date:  2006-04-26       Impact factor: 6.167

Review 8.  Nicotine and inflammatory neurological disorders.

Authors:  Wen-Hua Piao; Denise Campagnolo; Carlos Dayao; Ronald J Lukas; Jie Wu; Fu-Dong Shi
Journal:  Acta Pharmacol Sin       Date:  2009-05-18       Impact factor: 6.150

Review 9.  Novel therapeutic strategies in Parkinson's disease.

Authors:  Peter Klivenyi; Laszlo Vecsei
Journal:  Eur J Clin Pharmacol       Date:  2009-10-16       Impact factor: 2.953

10.  Effects of nicotine and mecamylamine on cognition in rhesus monkeys.

Authors:  Simon N Katner; Sophia A Davis; Amber J Kirsten; Michael A Taffe
Journal:  Psychopharmacology (Berl)       Date:  2004-04-27       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.